is under clinical development by biopharmaceutical company AstraZeneca and is currently in a Phase III study. The drug candidate is administered orally in the form of a film-coated tablet and acts ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...